BioMarin Pharmaceutical (NASDAQ:BMRN) Vs. AMGN, GILD, REGN, VRTX, BIIB, SGEN, ALNY, INCY, EXAS, and RGEN
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Exact Sciences (EXAS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.
BioMarin Pharmaceutical vs.
Gilead Sciences (NASDAQ:GILD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, community ranking, institutional ownership and dividends.
Gilead Sciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
78.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 94.2% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 1.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Gilead Sciences currently has a consensus target price of $79.18, indicating a potential upside of 14.64%. BioMarin Pharmaceutical has a consensus target price of $112.57, indicating a potential upside of 30.90%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Gilead Sciences.
Gilead Sciences has a net margin of 26.91% compared to BioMarin Pharmaceutical's net margin of 0.86%. Gilead Sciences' return on equity of 56.59% beat BioMarin Pharmaceutical's return on equity.
Gilead Sciences received 922 more outperform votes than BioMarin Pharmaceutical when rated by MarketBeat users. Likewise, 79.18% of users gave Gilead Sciences an outperform vote while only 76.76% of users gave BioMarin Pharmaceutical an outperform vote.
BioMarin Pharmaceutical has lower revenue, but higher earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Gilead Sciences had 3 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Gilead Sciences and 12 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.12 beat Gilead Sciences' score of 0.00 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.
Summary
BioMarin Pharmaceutical beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical (NASDAQ:BMRN) vs. Its Competitors
BioMarin Pharmaceutical Competitors List
